{"id":47262,"date":"2022-08-12T20:01:48","date_gmt":"2022-08-12T18:01:48","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/seagen-statement-on-outcome-of-daiichi-sankyo-arbitration\/"},"modified":"2022-08-12T20:01:48","modified_gmt":"2022-08-12T18:01:48","slug":"seagen-statement-on-outcome-of-daiichi-sankyo-arbitration","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/seagen-statement-on-outcome-of-daiichi-sankyo-arbitration\/","title":{"rendered":"Seagen Statement on Outcome of Daiichi Sankyo Arbitration"},"content":{"rendered":"
\n

BOTHELL, Wash.–(BUSINESS WIRE)–Seagen Inc. (Nasdaq: SGEN) today issued a statement regarding the outcome of the arbitration with Daiichi Sankyo Co. Ltd. (\u201cDaiichi Sankyo\u201d) relating to the parties\u2019 2008 collaboration agreement for the use of Seagen\u2019s antibody-drug conjugate (ADC) technology. The arbitrator ruled in favor of Daiichi Sankyo, citing statute of limitations and disagreement with Seagen on the interpretation of the contract.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWhile we are disappointed with the arbitration decision, it was important for us to pursue this legal action,\u201d said Roger Dansey, M.D., interim Chief Executive Officer and Chief Medical Officer, Seagen. \u201cThis does not impact our existing business. Looking forward, we are well-positioned to drive continued innovation and growth with four commercial products and a deep and diverse pipeline of promising programs. Seagen remains focused on developing innovative medicines that make a meaningful difference in the lives of cancer patients.\u201d\n<\/p>\n

\nAbout Seagen<\/b>\n<\/p>\n

\nSeagen Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people\u2019s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company\u2019s marketed products and robust pipeline, visit www.seagen.com<\/a> and follow @SeagenGlobal on Twitter.\n<\/p>\n

\nForward Looking Statements<\/b>\n<\/p>\n

\nCertain of the statements made in this press release are forward looking, such as those, among others, relating to Seagen\u2019s continued innovation and growth, as well as its pipeline. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, the risk that the company\u2019s financial results may not be as expected and the difficulty and uncertainty of pharmaceutical product development. More information about the risks and uncertainties faced by the company is contained under the caption \u201cRisk Factors\u201d included in Seagen\u2019s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise except as required by applicable law.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nFor Media<\/b>
David Caouette
\n
(310) 430-3476
\n
dcaouette@seagen.com<\/a>\n<\/p>\n

\nFor Investors<\/b>
Peggy Pinkston
\n
(425) 527-4160
\n
ppinkston@seagen.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BOTHELL, Wash.–(BUSINESS WIRE)–Seagen Inc. (Nasdaq: SGEN) today issued a statement regarding the outcome of the arbitration with Daiichi Sankyo Co. Ltd. (\u201cDaiichi Sankyo\u201d) relating to the parties\u2019 2008 collaboration agreement for the use of Seagen\u2019s antibody-drug conjugate (ADC) technology. The arbitrator ruled in favor of Daiichi Sankyo, citing statute of limitations and disagreement with Seagen … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47262","6":"format-standard","7":"category-industry"},"yoast_head":"\nSeagen Statement on Outcome of Daiichi Sankyo Arbitration - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/seagen-statement-on-outcome-of-daiichi-sankyo-arbitration\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Seagen Statement on Outcome of Daiichi Sankyo Arbitration - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BOTHELL, Wash.–(BUSINESS WIRE)–Seagen Inc. (Nasdaq: SGEN) today issued a statement regarding the outcome of the arbitration with Daiichi Sankyo Co. Ltd. (\u201cDaiichi Sankyo\u201d) relating to the parties\u2019 2008 collaboration agreement for the use of Seagen\u2019s antibody-drug conjugate (ADC) technology. The arbitrator ruled in favor of Daiichi Sankyo, citing statute of limitations and disagreement with Seagen ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/seagen-statement-on-outcome-of-daiichi-sankyo-arbitration\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-12T18:01:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220812005378\/en\/828587\/21\/Seagen_Logo_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seagen-statement-on-outcome-of-daiichi-sankyo-arbitration\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seagen-statement-on-outcome-of-daiichi-sankyo-arbitration\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Seagen Statement on Outcome of Daiichi Sankyo Arbitration\",\"datePublished\":\"2022-08-12T18:01:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seagen-statement-on-outcome-of-daiichi-sankyo-arbitration\\\/\"},\"wordCount\":386,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seagen-statement-on-outcome-of-daiichi-sankyo-arbitration\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220812005378\\\/en\\\/828587\\\/21\\\/Seagen_Logo_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seagen-statement-on-outcome-of-daiichi-sankyo-arbitration\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seagen-statement-on-outcome-of-daiichi-sankyo-arbitration\\\/\",\"name\":\"Seagen Statement on Outcome of Daiichi Sankyo Arbitration - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seagen-statement-on-outcome-of-daiichi-sankyo-arbitration\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seagen-statement-on-outcome-of-daiichi-sankyo-arbitration\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220812005378\\\/en\\\/828587\\\/21\\\/Seagen_Logo_RGB.jpg\",\"datePublished\":\"2022-08-12T18:01:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seagen-statement-on-outcome-of-daiichi-sankyo-arbitration\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seagen-statement-on-outcome-of-daiichi-sankyo-arbitration\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seagen-statement-on-outcome-of-daiichi-sankyo-arbitration\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220812005378\\\/en\\\/828587\\\/21\\\/Seagen_Logo_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220812005378\\\/en\\\/828587\\\/21\\\/Seagen_Logo_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seagen-statement-on-outcome-of-daiichi-sankyo-arbitration\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Seagen Statement on Outcome of Daiichi Sankyo Arbitration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Seagen Statement on Outcome of Daiichi Sankyo Arbitration - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/seagen-statement-on-outcome-of-daiichi-sankyo-arbitration\/","og_locale":"en_US","og_type":"article","og_title":"Seagen Statement on Outcome of Daiichi Sankyo Arbitration - Pharma Trend","og_description":"BOTHELL, Wash.–(BUSINESS WIRE)–Seagen Inc. (Nasdaq: SGEN) today issued a statement regarding the outcome of the arbitration with Daiichi Sankyo Co. Ltd. (\u201cDaiichi Sankyo\u201d) relating to the parties\u2019 2008 collaboration agreement for the use of Seagen\u2019s antibody-drug conjugate (ADC) technology. The arbitrator ruled in favor of Daiichi Sankyo, citing statute of limitations and disagreement with Seagen ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/seagen-statement-on-outcome-of-daiichi-sankyo-arbitration\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-12T18:01:48+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220812005378\/en\/828587\/21\/Seagen_Logo_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/seagen-statement-on-outcome-of-daiichi-sankyo-arbitration\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/seagen-statement-on-outcome-of-daiichi-sankyo-arbitration\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Seagen Statement on Outcome of Daiichi Sankyo Arbitration","datePublished":"2022-08-12T18:01:48+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/seagen-statement-on-outcome-of-daiichi-sankyo-arbitration\/"},"wordCount":386,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/seagen-statement-on-outcome-of-daiichi-sankyo-arbitration\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220812005378\/en\/828587\/21\/Seagen_Logo_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/seagen-statement-on-outcome-of-daiichi-sankyo-arbitration\/","url":"https:\/\/pharma-trend.com\/en\/seagen-statement-on-outcome-of-daiichi-sankyo-arbitration\/","name":"Seagen Statement on Outcome of Daiichi Sankyo Arbitration - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/seagen-statement-on-outcome-of-daiichi-sankyo-arbitration\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/seagen-statement-on-outcome-of-daiichi-sankyo-arbitration\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220812005378\/en\/828587\/21\/Seagen_Logo_RGB.jpg","datePublished":"2022-08-12T18:01:48+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/seagen-statement-on-outcome-of-daiichi-sankyo-arbitration\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/seagen-statement-on-outcome-of-daiichi-sankyo-arbitration\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/seagen-statement-on-outcome-of-daiichi-sankyo-arbitration\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220812005378\/en\/828587\/21\/Seagen_Logo_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220812005378\/en\/828587\/21\/Seagen_Logo_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/seagen-statement-on-outcome-of-daiichi-sankyo-arbitration\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Seagen Statement on Outcome of Daiichi Sankyo Arbitration"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47262","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47262"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47262\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47262"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47262"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47262"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}